Enzychem Lifesciences Corporation (183490.KQ)
KRW 1080.0
(0.19%)
KRW 1080.0
(0.19%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -14.35 Billion KRW | 0.47% |
| 2022 | -14.8 Billion KRW | 28.67% |
| 2021 | -20.75 Billion KRW | -16.4% |
| 2020 | -17.82 Billion KRW | -8.7% |
| 2019 | -16.4 Billion KRW | -9.57% |
| 2018 | -14.97 Billion KRW | -177.43% |
| 2017 | -5.39 Billion KRW | 13.34% |
| 2016 | -6.22 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -2.15 Billion KRW | 40.24% |
| 2024 Q2 | -3.63 Billion KRW | -68.63% |
| 2023 Q4 | -3.6 Billion KRW | 15.09% |
| 2023 Q1 | -3.05 Billion KRW | 14.8% |
| 2023 Q2 | -3.83 Billion KRW | -25.45% |
| 2023 FY | -14.73 Billion KRW | 0.47% |
| 2023 Q3 | -4.24 Billion KRW | -10.78% |
| 2022 Q2 | -3.6 Billion KRW | 21.6% |
| 2022 FY | -14.8 Billion KRW | 28.67% |
| 2022 Q4 | -3.58 Billion KRW | -20.96% |
| 2022 Q3 | -2.96 Billion KRW | 17.79% |
| 2022 Q1 | -4.59 Billion KRW | 11.73% |
| 2021 Q1 | -5.51 Billion KRW | 17.13% |
| 2021 FY | -20.75 Billion KRW | -16.4% |
| 2021 Q4 | -5.2 Billion KRW | -0.37% |
| 2021 Q3 | -5.18 Billion KRW | -6.81% |
| 2021 Q2 | -4.85 Billion KRW | 11.87% |
| 2020 Q4 | -6.65 Billion KRW | -25.22% |
| 2020 Q3 | -5.31 Billion KRW | -69.8% |
| 2020 Q1 | -4.01 Billion KRW | -19.76% |
| 2020 Q2 | -3.12 Billion KRW | 22.06% |
| 2020 FY | -17.82 Billion KRW | -8.7% |
| 2019 Q3 | -5.23 Billion KRW | -17.84% |
| 2019 Q1 | -3.38 Billion KRW | -9.99% |
| 2019 FY | -16.4 Billion KRW | -9.57% |
| 2019 Q4 | -3.35 Billion KRW | 35.92% |
| 2019 Q2 | -4.43 Billion KRW | -31.31% |
| 2018 FY | -14.97 Billion KRW | -177.43% |
| 2018 Q2 | -2.55 Billion KRW | 59.86% |
| 2018 Q4 | -3.07 Billion KRW | -32.49% |
| 2018 Q3 | -2.31 Billion KRW | 9.37% |
| 2018 Q1 | -6.37 Billion KRW | -976.53% |
| 2017 Q2 | -1.42 Billion KRW | 0.0% |
| 2017 FY | -5.39 Billion KRW | 13.34% |
| 2017 Q3 | -1.58 Billion KRW | -11.26% |
| 2017 Q4 | -592.3 Million KRW | 62.74% |
| 2016 FY | -6.22 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | -19.54 Billion KRW | 26.538% |
| CMG Pharmaceutical Co., Ltd. | 5.72 Billion KRW | 350.754% |
| Celltrion Pharm, Inc. | 36.07 Billion KRW | 139.8% |
| Huons Global Co., Ltd. | 122.92 Billion KRW | 111.679% |
| DongKook Pharmaceutical Co., Ltd. | 66.87 Billion KRW | 121.468% |
| Humedix Co., Ltd. | 37.31 Billion KRW | 138.478% |
| Boditech Med Inc. | 33.44 Billion KRW | 142.927% |
| EuBiologics Co., Ltd. | 7.69 Billion KRW | 286.465% |
| FutureChem Co.,Ltd | -8.4 Billion KRW | -70.746% |
| Huons Co., Ltd. | 59.79 Billion KRW | 124.009% |
| BNC Korea Co., Ltd. | 10.81 Billion KRW | 232.698% |
| AptaBio Therapeutics Inc. | -16.37 Billion KRW | 12.321% |